Axogen Inc. (AXGN) 2.68 $AXGN
AxoGen, Inc. Appoints Lee Robert Johnston, Jr. Chief Financial Officer
GlobeNewswire - Mon May 12, 3:08PM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the $1.6 billion US peripheral nerve repair market, announced the appointment of Lee Robert Johnston, Jr, as Chief Financial Officer, effective May 12, 2014. Mr. Johnston will report directly to Karen Zaderej, President and Chief Executive Officer.
AxoGen, Inc. Selected to Present at SEMDA 2014 Conference
GlobeNewswire - Mon May 05, 8:42AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the $1.6 billion U.S. peripheral nerve repair market, announced today that it has been selected from a record number of applicants as a presenting company at the 2014 Conference of the Southeastern Medical Device Association (SEMDA). The eighth annual SEMDA Conference, "Thriving During Healthcare Reform," will be held May 7-8, 2014, at the Renaissance Atlanta Waverly Hotel and Convention Center in Atlanta.
AxoGen, Inc. Reports 46% First Quarter Revenue Growth
GlobeNewswire - Wed Apr 30, 3:13PM CDT
via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), a leading medical technology company focused on the $1.6 billion U.S. peripheral nerve repair market, announced financial results for the first quarter ended March 31, 2014. Revenue for the quarter grew 46% to $3.14 million compared to $2.14 million for the first quarter of 2013.
AxoGen, Inc. to Exhibit in the American College of Oral and Maxillofacial Surgeons 2014 Annual Meeting
GlobeNewswire - Mon Apr 28, 6:14AM CDT
via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), the emerging leader of the $1.6 billion U.S. peripheral nerve repair market, announced today that it will be highlighting its products at the American College of Oral and Maxillofacial (ACOMS) 35th Annual Scientific Conference and Exhibition, April 27-30 in Las Vegas, Nevada. AxoGen is exhibiting its full portfolio of nerve repair and protection technologies and products at Booth 22.
AxoGen (AXGN) in Focus: Stock Moves 5.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 8:18AM CDT
AxoGen, Inc. (AXGN) was a big mover last session, as the company saw its shares rise by roughly 6% on the day.
AxoGen, Inc. to Report First Quarter Financial Results on April 30, 2014
GlobeNewswire - Wed Apr 16, 6:03AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), the emerging leader of the $1.6 billion U.S. peripheral nerve repair market, will report results for the first quarter ended March 31, 2014 on Wednesday, April 30, 2014 after the market closes.
AxoGen, Inc. to Exhibit Nerve Repair Portfolio at American Academy of Orthopedic Surgeons 2014 Annual Meeting
GlobeNewswire - Wed Mar 12, 6:02AM CDT
via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), the emerging leader of the $1.6 billion U.S. peripheral nerve repair market, is pleased to announce its participation at the American Academy of Orthopedic Surgeons (AAOS) 2014 Annual Meeting, March 11-15, 2014 at the Morial Convention Center in New Orleans, LA, Booth 5818.
AxoGen, Inc. Reports 46% Fourth Quarter and 42% Full Year 2013 Revenue Growth
GlobeNewswire - Fri Mar 07, 2:59AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), the emerging leader of the $1.6 billion U.S. peripheral nerve repair market, announced financial results for the fourth quarter and full year ended December 31, 2013. Revenue for the quarter grew 46% to $3.0 million and for the year grew 42% to $10.9 million as compared to comparable periods.
AxoGen, Inc. to Present at Canaccord Genuity Musculoskeletal Conference
GlobeNewswire - Mon Mar 03, 6:03AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), the only company completely focused on peripheral nerve repair, is scheduled to present at the 9th Annual Canaccord Genuity Musculoskeletal Conference on Tuesday, March 11, 2014 at 11:10am CT (12:10pm ET) at the Sheraton New Orleans Hotel.
AxoGen, Inc. to Report Fourth Quarter and Full Year 2013 Financial Results on March 6, 2014
GlobeNewswire - Wed Feb 12, 6:04AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), the only company completely focused on peripheral nerve repair, will report results for the fourth quarter and full year ended December 31, 2013 on Thursday, March 6, 2014 after the market closes.
AxoGen, Inc. Announces Presentation of New Clinical Data For Avance(R) Nerve Graft
GlobeNewswire - Thu Feb 06, 6:03AM CST
via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), the only company completely focused on peripheral nerve repair, today announced that new data from the CHANGE Study and the Ranger(R) Study was presented by study investigators at the recent combined annual meetings of the American Association for Hand Surgery (AAHS), American Society for Peripheral Nerve (ASPN) and American Society for Reconstructive Microsurgery (ASRM).
AxoGen, Inc. Gives Presentation on Nerve Repair Science at International Conference
GlobeNewswire - Fri Jan 24, 6:03AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), the only medical products company completely focused on peripheral nerve repair, today announced the acceptance of a scientific presentation on nerve repair at the International Symposium on Peripheral Nerve Regeneration (ISPNR) 2014 Meeting. The symposium, being held in Torino, Italy, acts as a platform for presenting and discussing new developments in the field of nerve regeneration and tissue engineering and attracts clinicians and researchers from across the globe.
AxoGen, Inc. to Present at Noble Financial Capital Markets' Tenth Annual Equity Conference
GlobeNewswire - Tue Jan 21, 6:03AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), the only medical products company completely focused on peripheral nerve repair, today announced that Greg Freitag, AxoGen's Chief Financial Officer and General Counsel, is scheduled to present at "TEN"; Noble Financial Capital Markets' Tenth Annual Equity Conference at Club Med in Sandpiper Bay, Florida on Wednesday, January 22, 2014 at 8:30 am ET.
Insureon CEO: Technology Investments Key to Acquisition Target Insurance Noodle
Fran Lysiak - AMBest - Fri Jan 10, 3:44PM CST
Insureon, an online commercial insurance broker and technology company, has agreed to acquire Insurance Noodle, the online wholesale broker and subsidiary of Willis Group Holdings.
Gerald Commissiong, CEO of Amarantus to Participate in Twitter Chat, "The Human Brain"
GlobeNewswire - Thu Jan 09, 2:58PM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced that the Company's President and CEO, Gerald E. Commissiong will participate in a Twitter chat tonight at 9:00 PM ET on the topic, "The Human Brain."
AxoGen, Inc. to Sponsor "Current Concepts for Improving Nerve Repair Outcomes" at the American Association for Hand Surgery (AAHS) Annual Meeting
GlobeNewswire - Thu Jan 09, 6:02AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), the only regenerative medicine company completely focused on peripheral nerve repair, today announced that it will sponsor a lunch symposium and panel discussion at the combined annual meetings of the American Association for Hand Surgery (AAHS), American Society for Peripheral Nerve (ASPN) and American Society for Reconstructive Microsurgery (ASRM) taking place January 8-14, 2014 in Kauai, Hawaii.
AxoGen Receives Product Innovation Leadership Award from Frost & Sullivan
GlobeNewswire - Mon Jan 06, 1:32PM CST
via PRWEB - AxoGen, Inc. (NASDAQ:AXGN), the only regenerative medicine company completely focused on peripheral nerve repair, has been awarded the 2014 North American New Product Innovation Leadership Award for Peripheral Nerve Repair by the preeminent global research organization, Frost & Sullivan. The award is based on the findings of Frost & Sullivan's Best Practices Research Team which studied the nearly one million peripheral nerve injury repair procedures performed every year in the United States and recognized AxoGen for developing and commercializing the Avance(R) Nerve Graft.
Frost & Sullivan Applaud AxoGen's Proprietary Process for Producing Decellularized Nerve Allografts
PR Newswire Europe - Mon Jan 06, 6:45AM CST
-- AxoGen is the only regenerative medicine company that is completely focused on peripheral nerve repair
Nasdaq stocks posting largest volume increases
AP - Thu Jan 02, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
AxoGen, Inc. Appoints Lee Robert Johnston, Jr. Chief Financial Officer
GlobeNewswire - Mon May 12, 3:08PM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the $1.6 billion US peripheral nerve repair market, announced the appointment of Lee Robert Johnston, Jr, as Chief Financial Officer, effective May 12, 2014. Mr. Johnston will report directly to Karen Zaderej, President and Chief Executive Officer.
AxoGen, Inc. Selected to Present at SEMDA 2014 Conference
GlobeNewswire - Mon May 05, 8:42AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the $1.6 billion U.S. peripheral nerve repair market, announced today that it has been selected from a record number of applicants as a presenting company at the 2014 Conference of the Southeastern Medical Device Association (SEMDA). The eighth annual SEMDA Conference, "Thriving During Healthcare Reform," will be held May 7-8, 2014, at the Renaissance Atlanta Waverly Hotel and Convention Center in Atlanta.
AxoGen, Inc. Reports 46% First Quarter Revenue Growth
GlobeNewswire - Wed Apr 30, 3:13PM CDT
via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), a leading medical technology company focused on the $1.6 billion U.S. peripheral nerve repair market, announced financial results for the first quarter ended March 31, 2014. Revenue for the quarter grew 46% to $3.14 million compared to $2.14 million for the first quarter of 2013.
AxoGen, Inc. to Exhibit in the American College of Oral and Maxillofacial Surgeons 2014 Annual Meeting
GlobeNewswire - Mon Apr 28, 6:14AM CDT
via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), the emerging leader of the $1.6 billion U.S. peripheral nerve repair market, announced today that it will be highlighting its products at the American College of Oral and Maxillofacial (ACOMS) 35th Annual Scientific Conference and Exhibition, April 27-30 in Las Vegas, Nevada. AxoGen is exhibiting its full portfolio of nerve repair and protection technologies and products at Booth 22.
AxoGen (AXGN) in Focus: Stock Moves 5.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 8:18AM CDT
AxoGen, Inc. (AXGN) was a big mover last session, as the company saw its shares rise by roughly 6% on the day.
AxoGen, Inc. to Report First Quarter Financial Results on April 30, 2014
GlobeNewswire - Wed Apr 16, 6:03AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), the emerging leader of the $1.6 billion U.S. peripheral nerve repair market, will report results for the first quarter ended March 31, 2014 on Wednesday, April 30, 2014 after the market closes.
AxoGen, Inc. to Exhibit Nerve Repair Portfolio at American Academy of Orthopedic Surgeons 2014 Annual Meeting
GlobeNewswire - Wed Mar 12, 6:02AM CDT
via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), the emerging leader of the $1.6 billion U.S. peripheral nerve repair market, is pleased to announce its participation at the American Academy of Orthopedic Surgeons (AAOS) 2014 Annual Meeting, March 11-15, 2014 at the Morial Convention Center in New Orleans, LA, Booth 5818.
AxoGen, Inc. Reports 46% Fourth Quarter and 42% Full Year 2013 Revenue Growth
GlobeNewswire - Fri Mar 07, 2:59AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), the emerging leader of the $1.6 billion U.S. peripheral nerve repair market, announced financial results for the fourth quarter and full year ended December 31, 2013. Revenue for the quarter grew 46% to $3.0 million and for the year grew 42% to $10.9 million as compared to comparable periods.
AxoGen, Inc. to Present at Canaccord Genuity Musculoskeletal Conference
GlobeNewswire - Mon Mar 03, 6:03AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), the only company completely focused on peripheral nerve repair, is scheduled to present at the 9th Annual Canaccord Genuity Musculoskeletal Conference on Tuesday, March 11, 2014 at 11:10am CT (12:10pm ET) at the Sheraton New Orleans Hotel.
AxoGen, Inc. to Report Fourth Quarter and Full Year 2013 Financial Results on March 6, 2014
GlobeNewswire - Wed Feb 12, 6:04AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), the only company completely focused on peripheral nerve repair, will report results for the fourth quarter and full year ended December 31, 2013 on Thursday, March 6, 2014 after the market closes.
AxoGen, Inc. Announces Presentation of New Clinical Data For Avance(R) Nerve Graft
GlobeNewswire - Thu Feb 06, 6:03AM CST
via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), the only company completely focused on peripheral nerve repair, today announced that new data from the CHANGE Study and the Ranger(R) Study was presented by study investigators at the recent combined annual meetings of the American Association for Hand Surgery (AAHS), American Society for Peripheral Nerve (ASPN) and American Society for Reconstructive Microsurgery (ASRM).
AxoGen, Inc. Gives Presentation on Nerve Repair Science at International Conference
GlobeNewswire - Fri Jan 24, 6:03AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), the only medical products company completely focused on peripheral nerve repair, today announced the acceptance of a scientific presentation on nerve repair at the International Symposium on Peripheral Nerve Regeneration (ISPNR) 2014 Meeting. The symposium, being held in Torino, Italy, acts as a platform for presenting and discussing new developments in the field of nerve regeneration and tissue engineering and attracts clinicians and researchers from across the globe.
AxoGen, Inc. to Present at Noble Financial Capital Markets' Tenth Annual Equity Conference
GlobeNewswire - Tue Jan 21, 6:03AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), the only medical products company completely focused on peripheral nerve repair, today announced that Greg Freitag, AxoGen's Chief Financial Officer and General Counsel, is scheduled to present at "TEN"; Noble Financial Capital Markets' Tenth Annual Equity Conference at Club Med in Sandpiper Bay, Florida on Wednesday, January 22, 2014 at 8:30 am ET.
Insureon CEO: Technology Investments Key to Acquisition Target Insurance Noodle
Fran Lysiak - AMBest - Fri Jan 10, 3:44PM CST
Insureon, an online commercial insurance broker and technology company, has agreed to acquire Insurance Noodle, the online wholesale broker and subsidiary of Willis Group Holdings.
Gerald Commissiong, CEO of Amarantus to Participate in Twitter Chat, "The Human Brain"
GlobeNewswire - Thu Jan 09, 2:58PM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced that the Company's President and CEO, Gerald E. Commissiong will participate in a Twitter chat tonight at 9:00 PM ET on the topic, "The Human Brain."
AxoGen, Inc. to Sponsor "Current Concepts for Improving Nerve Repair Outcomes" at the American Association for Hand Surgery (AAHS) Annual Meeting
GlobeNewswire - Thu Jan 09, 6:02AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), the only regenerative medicine company completely focused on peripheral nerve repair, today announced that it will sponsor a lunch symposium and panel discussion at the combined annual meetings of the American Association for Hand Surgery (AAHS), American Society for Peripheral Nerve (ASPN) and American Society for Reconstructive Microsurgery (ASRM) taking place January 8-14, 2014 in Kauai, Hawaii.
AxoGen Receives Product Innovation Leadership Award from Frost & Sullivan
GlobeNewswire - Mon Jan 06, 1:32PM CST
via PRWEB - AxoGen, Inc. (NASDAQ:AXGN), the only regenerative medicine company completely focused on peripheral nerve repair, has been awarded the 2014 North American New Product Innovation Leadership Award for Peripheral Nerve Repair by the preeminent global research organization, Frost & Sullivan. The award is based on the findings of Frost & Sullivan's Best Practices Research Team which studied the nearly one million peripheral nerve injury repair procedures performed every year in the United States and recognized AxoGen for developing and commercializing the Avance(R) Nerve Graft.
Frost & Sullivan Applaud AxoGen's Proprietary Process for Producing Decellularized Nerve Allografts
PR Newswire Europe - Mon Jan 06, 6:45AM CST
-- AxoGen is the only regenerative medicine company that is completely focused on peripheral nerve repair
Nasdaq stocks posting largest volume increases
AP - Thu Jan 02, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
